Viewing Study NCT00301405



Ignite Creation Date: 2024-05-05 @ 4:43 PM
Last Modification Date: 2024-10-26 @ 9:23 AM
Study NCT ID: NCT00301405
Status: TERMINATED
Last Update Posted: 2013-08-05
First Post: 2006-03-09

Brief Title: Open-Label Study of Thalidomide for Chronic ProstatitisChronic Pelvic Pain
Sponsor: Kenneth Peters MD
Organization: William Beaumont Hospitals

Study Overview

Official Title: Open-Label Study of Thalidomide for Chronic ProstatitisChronic Pelvic Pain
Status: TERMINATED
Status Verified Date: 2013-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Study closed Difficult enrollment of patients with prostatitis
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To determine the efficacy of thalidomide for treatment of the Chronic Pelvic Pain Syndrome CPPS
Detailed Description: Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men In Chronic Prostatitis CP or Chronic Pelvic Pain Syndrome CPPS men have lower urinary tract symptoms pelvic pain sexual dysfunction and decreased quality of life Little is known about the cause of CPCPPS and no definitive therapy exists

Thalidomide is an immunomodulator a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth Therefore in theory it may reduce or prevent the growth of cancer cells Thalidomide is approved by the Food and Drug Administration FDA for a leprosy skin condition but not for the treatment of CP or CPPS

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None